BioHealth Innovation, Inc.

Albine Martin is a C-level executive with more than thirty years of experience moving innovations from the laboratory to clinical application. As an Executive in Residence, she works on evaluating innovations and intellectual property portfolios for company formation and supports the regional startup ecosystem. She holds a Ph.D. in Biochemistry from the University of Maryland, College Park, a B.S. from Trinity College in Washington, DC, and executive education certificates from Cornell University and Harvard Business School.

Charles D. Buchen is a biopharmaceutical executive with more than 15 years of experience in business development, strategic transactions, and drug development, with a focus on oncology and rare diseases. He works as a consultant and advisor to multiple biotechnology companies and remains involved in clinical research and translational medicine.

Diane M. Ignar, Ph.D., is a pharmaceutical executive and strategic advisor with more than 25 years of experience across the biopharmaceutical value chain, from discovery research through commercialization. Her work spans therapeutic development, business partnerships, emerging markets strategy, and technology innovation. She has experience in therapeutic areas including neuropharmacology, metabolic diseases, respiratory and allergic diseases, rare diseases, and oncology.

Business leader and operations executive with over 40 years of comprehensive experience in the biotechnology industry, specializing in manufacturing, quality assurance, regulatory affairs, and global operations.

Administrative professional and organizational leader with over a decade of experience in complex regulatory environments. Brings expertise in management studies and human resources to support mission-critical operations.

Jennifer Butler is a global commercial executive with nearly 20 years of experience helping biotechnology companies advance from early development to commercialization. She serves as Montgomery County's first "Executive in Residence," a role established through a collaboration between Montgomery County and BioHealth Innovation, Inc. (BHI) to provide technical assistance to local biotech startups.

Jessica E. Foley is a senior regulatory professional with over 18 years of experience in healthcare, due diligence, global biopharmaceutical development strategy, and regulatory submissions. She is the Principal Consultant and Founder of Gaia Regulatory Sciences, LLC in Cambridge, MA, providing regulatory strategy and project management support to pharmaceutical and biotech companies. She holds a Master of Science in Regulatory Affairs for Drugs, Biologics, & Medical Devices and a Graduate Certificate in Biopharmaceutical International Regulatory Affairs from Northeastern University, and a Bachelor of Arts in Psychology from the University of New Hampshire; she is a certified Regulatory Affairs Professional (RAC-Global).

John K. Hsu, Ph.D., J.D., is an intellectual property attorney and patent litigator with more than twenty years of experience in pharmaceutical and technology litigation. He has represented clients in over sixty patent, trademark, and trade secret cases spanning industries including pharmaceutical drugs, medical devices, computer software, and food processing technology. He combines scientific training with legal expertise.

Jonathan B. Kay, MPP, serves as an Executive-in-Residence at BioHealth Innovation, where he provides strategic technical assistance to biotech and life sciences startups to support technological innovation and regional job creation. He advises the life sciences industry with expertise spanning biotech, pharmaceuticals, medical devices, diagnostics, vaccines, and digital health, including AI applications in healthcare.

Joseph DiCesare is a pharmaceutical industry executive with more than 30 years of experience in health economics and outcomes research (HEOR), real-world evidence (RWE), and strategic planning. He has held leadership roles at pharmaceutical companies and consulting organizations, focusing on economic analysis and evidence generation to demonstrate the value of pharmaceutical innovations.

Dr. Kevin N. Heller is a physician-scientist and drug development executive with more than 20 years of experience in oncology research and biopharmaceutical development. His work covers the full drug development lifecycle from discovery to commercialization, with focus areas in immuno-oncology, precision medicine, and regulatory strategy across both academia and industry.

Kimberly E. Martin is a scientific and clinical affairs executive with more than 25 years of experience bringing drugs and medical devices to market. She serves as an Entrepreneur-in-Residence and advisor to the National Institutes of Health (NIH), with expertise in clinical trial design and regulatory strategy across pharmaceutical and medical device development in multiple therapeutic areas.

Luis T. Gutierrez, Jr. is a business leader and entrepreneur with more than 25 years of experience commercializing medical technologies and helping startups grow into commercial enterprises. He has focused on developing life science products and services and currently holds several strategic advisory roles while remaining involved in company building and technology commercialization.

Finance and operations leader with over 15 years of experience managing accounting and financial teams for both for-profit and nonprofit organizations. Most recently served as Director of Finance & Administration and CFO at The IJIS Institute.

Marcella Garcia is a regulatory, quality, and compliance professional focused on medical devices, Software as a Medical Device (SaMD), and digital health technologies. She works as a Principal Consultant advising early-stage startups globally on regulatory pathways and quality management systems. She holds a B.S. in Electrical and Computer Engineering from Vanderbilt University and certifications including HCISPP from (ISC)², Certified SAFe Agile Scrum Master, and Cybersecurity for Managers from MIT Professional Education.

Monique Bennett is a scientist with a decade of experience in antibody discovery, vaccine science, and infectious disease. She holds a Master's degree in Cellular and Molecular Biology from the College of William and Mary and a PhD in Microbiology from Vanderbilt University Medical Center. She previously served as a Research Assistant Professor conducting clinical research on new vaccine targets and therapeutics for bacterial pathogens.

Life sciences executive and current Entrepreneur-in-Residence at ARPA-H with over two decades of experience in the life sciences tools industry and deep expertise in genomics.

Renée JG Arnold is President and CEO of Arnold Consultancy & Technology, LLC, where she leads outcomes research and develops related software for pharmaceutical and government programs, with a focus on using technology to collect and model real-world data for healthcare decision-making. She is also an Adjunct Professor in the Master of Public Health program at the Icahn School of Medicine at Mount Sinai, where she developed and teaches pharmacoeconomics coursework. She earned her undergraduate degree at the University of Maryland and her Doctor of Pharmacy from the University of Southern California, followed by a post-doctoral residency at University Hospital in San Diego/UCSF School of Pharmacy.

Todd B. Buck is an intellectual property attorney with over 20 years of experience advising startups, academic institutions, and corporations in the pharmaceutical, biotechnology, regenerative medicine, cell and gene therapy, and medical device fields. He holds a Ph.D. in Pharmacology and Toxicology from the University of Georgia and a J.D. from The George Washington University School of Law. His work covers patent strategy, trade secret protection, regulatory compliance, licensing, due diligence, and USPTO and Federal Circuit litigation, and he is admitted to the Georgia, North Carolina, Virginia, and District of Columbia Bars and registered with the USPTO.

Chris Chen oversees mission-aligned investments at Arnold Ventures, using tools such as equity, debt, and guarantees to support the organization's core issue areas. He previously was a partner at the Gates Foundation's Strategic Investment Fund, where he focused on early-stage biotechnology investments, and earlier served as a vice president on Bain Capital's private equity team investing in health care and industrial services. He holds an MBA from the Stanford Graduate School of Business and a bachelor's degree in Ethics, Politics, and Economics from Yale University.

Kirby Smith is Chief Strategy Officer at Arnold Ventures, which she joined in 2016, working across policy, advocacy, and operations to align strategy across the organization's programmatic areas. She has helped build the higher education team, worked on affordable housing that led to the creation of a mission-aligned investment team, and directs the incubation of new initiatives on issues such as sports betting and contraceptive access. Earlier she was a management consultant at Bain & Company focused on health care and financial services, and she holds MBA and MPP degrees from the University of Michigan and a bachelor's degree from Yale University.